Compare TGL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | INM |
|---|---|---|
| Founded | 2020 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 3.7M |
| IPO Year | 2022 | N/A |
| Metric | TGL | INM |
|---|---|---|
| Price | $8.51 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 893.9K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,305,713.00 | ★ $4,798,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $1.13 |
| 52 Week High | $780.00 | $8.27 |
| Indicator | TGL | INM |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 46.19 |
| Support Level | $0.26 | $1.28 |
| Resistance Level | $12.79 | $1.52 |
| Average True Range (ATR) | 6.19 | 0.11 |
| MACD | 0.75 | 0.03 |
| Stochastic Oscillator | 14.42 | 75.00 |
Treasure Global Inc. has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: (i) payment processing and e-commerce operation in its ZCITY platform, and (ii) customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.